Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.37 and has seen 0.87 million shares traded in the recent trading session. The company, currently valued at $820.58M, closed the recent trade at $2.27 per share which meant it gained $0.05 on the day or 2.25% during that session. The LXRX stock price is -64.32% off its 52-week high price of $3.73 and 59.47% above the 52-week low of $0.92. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.57 million shares traded. The 3-month trading volume is 2.67 million shares.
The consensus among analysts is that Lexicon Pharmaceuticals Inc (LXRX) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Sporting 2.25% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LXRX stock price touched $2.27 or saw a fall of -0.44%. Year-to-date, Lexicon Pharmaceuticals Inc shares have moved 48.37%, while the 5-day performance has seen it change 6.57%. Over the past 30 days, the shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) have changed 25.41%. Short interest in the company has seen 20.2 million shares shorted with days to cover at 7.86.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Figures show that Lexicon Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 41.87% over the past 6 months, with this year growth rate of 11.39%, compared to 15.30% for the industry. Revenue growth from the last financial year stood is estimated to be 1,902.50%.
5 analysts offering their estimates for the company have set an average revenue estimate of 2.83M for the current quarter. 6 have an estimated revenue figure of 8.96M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 6.80% over the past 5 years.
LXRX Dividends
Lexicon Pharmaceuticals Inc is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders own 1.15% of the company shares, while shares held by institutions stand at 72.83% with a share float percentage of 73.68%. Investors are also buoyed by the number of investors in a company, with Lexicon Pharmaceuticals Inc having a total of 163.0 institutions that hold shares in the company. The top two institutional holders are ARTAL GROUP S.A. with over 117.55 million shares worth more than $282.13 million. As of 2024-03-31, ARTAL GROUP S.A. held 53.1603% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 13.89 million shares as of 2024-03-31. The firm’s total holdings are worth over $33.35 million and represent 6.2832% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. As of May 31, 2024, the former fund manager holds about 1.15% shares in the company for having 4.15 shares of worth $9.59 million while later fund manager owns 3.71 shares of worth $8.57 million as of Mar 31, 2024, which makes it owner of about 1.03% of company’s outstanding stock.
